These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6376743)

  • 1. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.
    Levy J; Smith AL; Koup JR; Williams-Warren J; Ramsey B
    J Pediatr; 1984 Jul; 105(1):117-24. PubMed ID: 6376743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.
    Mann HJ; Canafax DM; Cipolle RJ; Daniels CE; Zaske DE; Warwick WJ
    Pediatr Pulmonol; 1985; 1(5):238-43. PubMed ID: 4069813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.
    Bauer LA; Piecoro JJ; Wilson HD; Blouin RA
    Clin Pharm; 1983; 2(3):262-4. PubMed ID: 6883955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis.
    Kildoo CW; Harralson AF; Folli HL; Kelly PC; Nussbaum E
    Drug Intell Clin Pharm; 1987; 21(7-8):639-42. PubMed ID: 3608813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
    Lim AK; Mathanasenarajah G; Larmour I
    Intern Med J; 2015 Mar; 45(3):319-29. PubMed ID: 25581282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Hermans J; Bakker W
    Ther Drug Monit; 1994 Apr; 16(2):125-31. PubMed ID: 8009558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
    Horrevorts AM; Degener JE; Dzoljic-Danilovic G; Michel MF; Kerrebijn KF; Driessen O; Hermans J
    Chest; 1985 Aug; 88(2):260-4. PubMed ID: 4017681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.
    Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tobramycin in cystic fibrosis.
    Kelly HB; Menendez R; Fan L; Murphy S
    J Pediatr; 1982 Feb; 100(2):318-21. PubMed ID: 7057342
    [No Abstract]   [Full Text] [Related]  

  • 10. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.
    Kearns GL; Hilman BC; Wilson JT
    J Pediatr; 1982 Feb; 100(2):312-8. PubMed ID: 7035640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study.
    de Groot R; Hack BD; Weber A; Chaffin D; Ramsey B; Smith AL
    Clin Pharmacol Ther; 1990 Jan; 47(1):73-8. PubMed ID: 2295222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime disposition in acute and stable cystic fibrosis.
    Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM
    Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.
    Hedman A; Alván G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1990 Feb; 18(2):168-75. PubMed ID: 2180614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis.
    Crass RL; Pai MP
    Clin Pharmacokinet; 2019 Oct; 58(10):1323-1332. PubMed ID: 30972695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of netilmicin in children with and without cystic fibrosis.
    Michalsen H; Bergan T
    Antimicrob Agents Chemother; 1981 Jun; 19(6):1029-31. PubMed ID: 7271272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults.
    Ziemniak JA; Assael BM; Padoan R; Schentag JJ
    Eur J Clin Pharmacol; 1984; 26(2):183-9. PubMed ID: 6723756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
    Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
    J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis.
    Town DJ; Vinks AA; Jacobs F; Heijerman HG; Bakker W
    Ther Drug Monit; 1996 Oct; 18(5):562-9. PubMed ID: 8885120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.
    Touw DJ; Vinks AA; Neef C
    Pharm World Sci; 1997 Jun; 19(3):142-51. PubMed ID: 9259030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.